Hydrocortisone in the management of acute hypoadrenocorticism in dogs: a retrospective series of 30 cases.
OBJECTIVE
The objectives of this study were to describe the efficacy, outcome and adverse effects of intravenous hydrocortisone and fluid therapy for the management of acute hypoadrenocorticism in dogs.


METHODS
A retrospective review of dogs with primary hypoadrenocorticism receiving intravenous hydrocortisone and fluid therapy was performed.


RESULTS
Thirty newly-diagnosed dogs were included. There was an excellent clinical response, with all dogs surviving to discharge within a median of 2 days. In 23 cases with complete data, the mean rate of change of sodium over 24 hours was 0·48 (±0·28) mmol/L/hour, while the mean rate of change of potassium was -0·12 (±0·06) mmol/L/hour. Circulating potassium concentration normalised in 68·4% and 100% of cases of by 12 and 24 hours, respectively. Additional treatment for hyperkalaemia was not found necessary. Plasma sodium concentration increased by >12 mmol/L/24 hours on 7 of 23 (30·4%) occasions. One dog exhibited associated temporary neurological signs.


CONCLUSIONS
Intravenous hydrocortisone infusion and fluid therapy for the management of acute hypoadrenocorticism is associated with a rapid resolution of hyperkalaemia and is well tolerated with few adverse effects. Regular electrolyte monitoring is required to ensure that rapid increases in sodium concentration are avoided.
Small Animal Clinical Studies, School of Veterinary Medicine, University College Dublin, Belfield, Dublin, 4, Ireland.
E
E
Gunn
Small Animal Clinical Studies, School of Veterinary Medicine, University College Dublin, Belfield, Dublin, 4, Ireland.
R E
RE
Shiel
Small Animal Clinical Studies, School of Veterinary Medicine, University College Dublin, Belfield, Dublin, 4, Ireland.
C T
CT
Mooney
D000309:Adrenal Insufficiency / Q000188:drug therapy / Q000662:veterinary*; D000818:Animals; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D005440:Fluid Therapy; D006854:Hydrocortisone / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D012189:Retrospective Studies
D006854:Hydrocortisone